How we do it
InnoCom makes investments into worthy Life Science companies, providing:
Investment opportunities in cutting edge technologies
Access to early commercialization for life Science innovators
Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing
Industry networking to access revenue at 2-3 years following pre-clinical trials
Providing revenue and/or takeout at 7 years end of clinical trials
Business Counsel and advice to the company management team
Corporate Officer participation, setting up strong Systems, Procedures, and Protocols
Board of Directors Membership, building strong Corporate Governance
Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years
Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years
Enhancing the delivery of health solutions to the patients who need them
-
Due Diligence Focus
Broad application for life sciences Fulfill a health need Novel technology Ip protection Early commercial potential Experienced management team Willing to partner for success
-
Approval
Fits novel life sciences portfolio Agree on operating and board principles Investor chooses investment to be made
-
Support for Success
C-Level Advisory Growth strategy Formulation advisory board Access Expedited value creation
-
Value Creation
Strategic Innovation investment licensing opportunities Flexible Exit options risk adverse investment
